Eunpi Cho1, Elahe A Mostaghel2, Kenneth J Russell3, Jay J Liao3, Mark A Konodi3, Brenda F Kurland4, Brett T Marck5, Alvin M Matsumoto6, Bruce L Dalkin3, R Bruce Montgomery7. 1. University of Washington School of Medicine, Seattle, Washington; Fred Hutchinson Cancer Research Center, Seattle, Washington. 2. Fred Hutchinson Cancer Research Center, Seattle, Washington. 3. University of Washington School of Medicine, Seattle, Washington. 4. University of Pittsburgh, Pittsburgh, Pennsylvania. 5. Veterans Affairs Puget Sound Health Care System, Seattle, Washington. 6. University of Washington School of Medicine, Seattle, Washington; Veterans Affairs Puget Sound Health Care System, Seattle, Washington. 7. University of Washington School of Medicine, Seattle, Washington. Electronic address: rbmontgo@uw.edu.
Abstract
PURPOSE: Optimizing androgen suppression may provide better control of localized prostate cancer (PCa). Numerous trials have supported the benefit of combining androgen deprivation therapy with definitive radiation therapy in men with locally advanced or high-grade disease. Addition of abiraterone to luteinizing hormone-releasing hormone agonist (LHRHa) with radiation has not been reported. We examined the safety of this combination as well as its impact on androgen suppression. METHODS AND MATERIALS: A prospective, phase 2 study was conducted in men with localized PCa treated with 6 months of neoadjuvant and concurrent abiraterone with LHRHa and radiation. Duration of adjuvant LHRHa was at the discretion of the treating clinician. Prostate biopsy assays were obtained prior to the start of therapy and prior to radiation. Sera and tissue androgen levels were measured by liquid chromatography-tandem mass spectrometry. RESULTS: A total of 22 men with intermediate- (n=3) and high-risk PCa (n=19) received study therapy. Sixteen men completed the intended course of abiraterone, and 19 men completed planned radiation to 77.4 to 81 Gy. Radiation to pelvic nodes was administered in 20 men. The following grade 3 toxicities were reported: lymphopenia (14 patients), fatigue (1 patient), transaminitis (2 patients), hypertension (2 patients), and hypokalemia (1 patient). There were no grade 4 toxicities. All 21 men who complied with at least 3 months of abiraterone therapy had a preradiation prostate-specific antigen (PSA) concentration nadir of <0.3 ng/mL. Median levels of tissue androgen downstream of CYP17A were significantly suppressed after treatment with abiraterone, and upstream steroids were increased. At median follow-up of 21 months (range: 3-37 months), only 1 patient (who had discontinued abiraterone at 3 months) had biochemical relapse. CONCLUSIONS: Addition of abiraterone to LHRHa with radiation is safe and achieves effective prostatic androgen suppression. Preliminary analysis of the clinical data is also promising, with excellent PSA nadir and no relapse to date in this high-risk population.
PURPOSE: Optimizing androgen suppression may provide better control of localized prostate cancer (PCa). Numerous trials have supported the benefit of combining androgen deprivation therapy with definitive radiation therapy in men with locally advanced or high-grade disease. Addition of abiraterone to luteinizing hormone-releasing hormone agonist (LHRHa) with radiation has not been reported. We examined the safety of this combination as well as its impact on androgen suppression. METHODS AND MATERIALS: A prospective, phase 2 study was conducted in men with localized PCa treated with 6 months of neoadjuvant and concurrent abiraterone with LHRHa and radiation. Duration of adjuvant LHRHa was at the discretion of the treating clinician. Prostate biopsy assays were obtained prior to the start of therapy and prior to radiation. Sera and tissue androgen levels were measured by liquid chromatography-tandem mass spectrometry. RESULTS: A total of 22 men with intermediate- (n=3) and high-risk PCa (n=19) received study therapy. Sixteen men completed the intended course of abiraterone, and 19 men completed planned radiation to 77.4 to 81 Gy. Radiation to pelvic nodes was administered in 20 men. The following grade 3 toxicities were reported: lymphopenia (14 patients), fatigue (1 patient), transaminitis (2 patients), hypertension (2 patients), and hypokalemia (1 patient). There were no grade 4 toxicities. All 21 men who complied with at least 3 months of abiraterone therapy had a preradiation prostate-specific antigen (PSA) concentration nadir of <0.3 ng/mL. Median levels of tissue androgen downstream of CYP17A were significantly suppressed after treatment with abiraterone, and upstream steroids were increased. At median follow-up of 21 months (range: 3-37 months), only 1 patient (who had discontinued abiraterone at 3 months) had biochemical relapse. CONCLUSIONS: Addition of abiraterone to LHRHa with radiation is safe and achieves effective prostatic androgen suppression. Preliminary analysis of the clinical data is also promising, with excellent PSA nadir and no relapse to date in this high-risk population.
Authors: Miljenko V Pilepich; Kathryn Winter; Colleen A Lawton; Robert E Krisch; Harvey B Wolkov; Benjamin Movsas; Eugen B Hug; Sucha O Asbell; David Grignon Journal: Int J Radiat Oncol Biol Phys Date: 2005-04-01 Impact factor: 7.038
Authors: P Lissoni; S Meregalli; E Bonetto; M Mancuso; F Brivio; M Colciago; G Gardani Journal: J Biol Regul Homeost Agents Date: 2005 Jul-Dec Impact factor: 1.711
Authors: Thomas F Kalhorn; Stephanie T Page; William N Howald; Elahe A Mostaghel; Peter S Nelson Journal: Rapid Commun Mass Spectrom Date: 2007 Impact factor: 2.419
Authors: Eric M Horwitz; Kyounghwa Bae; Gerald E Hanks; Arthur Porter; David J Grignon; Harmar D Brereton; Varagur Venkatesan; Colleen A Lawton; Seth A Rosenthal; Howard M Sandler; William U Shipley Journal: J Clin Oncol Date: 2008-04-14 Impact factor: 44.544
Authors: Atish D Choudhury; Kathryn P Gray; Jeffrey G Supko; Lauren C Harshman; Mary-Ellen Taplin; Amanda F Pace; Matthew Farina; Katherine A Zukotynski; Brandon Bernard; Philip W Kantoff; Mark Pomerantz; Christopher Sweeney Journal: Prostate Date: 2018-06-07 Impact factor: 4.104
Authors: Tianzhu Zang; Mary-Ellen Taplin; Daniel Tamae; Wanling Xie; Clementina Mesaros; Zhenwei Zhang; Glenn Bubley; Bruce Montgomery; Steven P Balk; Elahe A Mostaghel; Ian A Blair; Trevor M Penning Journal: Endocr Relat Cancer Date: 2017-06-29 Impact factor: 5.678
Authors: Elahe A Mostaghel; Eunpi Cho; Ailin Zhang; Mohammad Alyamani; Arja Kaipainen; Sean Green; Brett T Marck; Nima Sharifi; Jonathan L Wright; Roman Gulati; Lawrence D True; Massimo Loda; Alvin M Matsumoto; Daniel Tamae; Trevor N Penning; Steven P Balk; Phillip W Kantoff; Peter S Nelson; Mary-Ellen Taplin; R Bruce Montgomery Journal: Clin Cancer Res Date: 2017-04-07 Impact factor: 12.531
Authors: Rana R McKay; Lillian Werner; Elahe A Mostaghel; Rosina Lis; Olga Voznesensky; Zhenwei Zhang; Brett T Marck; Alvin M Matsumoto; Liran Domachevsky; Katherine A Zukotynski; Manoj Bhasin; Glenn J Bubley; Bruce Montgomery; Philip W Kantoff; Steven P Balk; Mary-Ellen Taplin Journal: Clin Cancer Res Date: 2016-09-28 Impact factor: 12.531
Authors: S M Green; A Kaipainen; K Bullock; A Zhang; J M Lucas; C Matson; W A Banks; E A Mostaghel Journal: Prostate Cancer Prostatic Dis Date: 2016-09-20 Impact factor: 5.554